Capital Structure

in mil. unless spec.
Working Capital

in mil. unless spec.
Growth Rates

in mil. unless spec.
Quarterly Revenue

in mil. unless spec.
Quarterly Earnings Per Share

in mil. unless spec.
Quarterly Dividends Per Share

in mil. unless spec.

Company Description

CEO
Mr. Jonathan Eitan Solomon MBA
Full Time Employees
58
Sector
Healthcare
Industry
Biotechnology
Address
22 Einstein Street Ness Ziona Israel 7414003
IPO Date
Mar 13, 2019
Website
biomx.com
Similar Companies
Business
BiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC). It is developing BX004, a phage therapy for CF patients with chronic Pseudomonas aeruginosa respiratory infections that is in Phase 1b/2a clinical trials. The company's pipeline products also include BX005, a topical phage cocktail, which is in Phase 1/2 clinical study that targets Staphylococcus aureus (S. aureus), a bacteria associated with the manifestation of the disease; and BX003, an orally administered phage cocktail, which is in Phase 1b/2a that targets a bacterial target present in the gut of IBD and PSC patients. In addition, the company engages in the provision of colorectal cancer program that utilizes engineered phage with various payloads, which are administered intravenously to target Fusobacterium nucleatum bacteria residing within the tumor microenvironment. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.

Company News

  • BiomX Inc. (PHGE) Q3 2024 Earnings Call Transcript

  • BiomX Announces Third Quarter 2024 Financial Results and Provides Business and Program Updates

  • BiomX to Host Third Quarter 2024 Financial Results Conference Call and Webcast on November 14, 2024

  • BiomX Announces a Mandatory Unit Separation

  • BiomX Stock Gains From Favorable Study Data Presentation on BX004

  • BiomX to Provide Latest Update on Positive Phase 1b/2a Clinical Trial Data for BX004 at the North American Cystic Fibrosis Conference

  • BiomX to Present at the H.C. Wainwright 26th Annual Global Investment Conference

  • UPDATE ON UNITS - BiomX Inc. Announces 1-for-10 Reverse Stock Split

  • BiomX Inc. (PHGE) Q2 2024 Earnings Call Transcript

  • BiomX Inc. Announces 1-for-10 Reverse Stock Split

  • BiomX Reports Second Quarter 2024 Financial Results and Provides Business and Program Updates

  • BiomX to Host Second Quarter 2024 Financial Results Conference Call and Webcast on August 15, 2024

  • BiomX Inc. Announces NYSE American Acceptance of Plan to Regain Listing Compliance

  • BiomX Inc. Announces Stockholder Approval for Conversion of Outstanding Series X Convertible Preferred Stock to Common Stock

  • BiomX Inc. Receives Notice of Non-Compliance with NYSE American Continued Listing Standards

  • BiomX to Present Phase 1b/2a Clinical Trial Data for BX004 at the 47th European Cystic Fibrosis Conference and at ASM Microbe 2024

  • BiomX (PHGE) Q1 2024 Earnings Call Transcript

  • BiomX Reports First Quarter 2024 Financial Results and Provides Business and Program Updates

  • BiomX to Host First Quarter 2024 Financial Results Conference Call and Webcast on May 21, 2024

  • BiomX to Present Data from Phase 1b/2a Study of BX004 for the Treatment of Cystic Fibrosis Patients with Chronic Pulmonary Infections at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2024)